Many faces of pulmonary aspergillosis

Aspergillus is a ubiquitous fungus. It is commonly isolated as an upper respiratory tract saprophyte and is the most frequent contaminant in laboratory specimens. Because species of aspergillus are omnipresent, one must be cautious in ascribing a causal role to the fungus obtained from patients. Aspergillus has low pathogenicity for humans and animals and rarely invades the immunologically competent host. Although the fungus can affect any organ system, the respiratory tract is involved in >90% of afflicted patients. Pulmonary aspergillosis, depending whether the host is atopic or immunosuppressed, may be classified under four categories: allergic or hypersensitivity syndromes, saprophytic colonization, invasive (infective) dissemination, and chemical or toxic pneumonitis. These entities differ clinically, radiologically, immunologically, and in their response to various therapeutic agents. An increased awareness, an aggressive approach to securing the diagnosis, and instituting early and appropriate therapy are needed to reduce the high morbidity and mortality caused by many of the aspergillus-related syndromes.

This article has been cited by other articles:

				H. Brodoefel, M. Vogel, H. Hebart, H. Einsele, R. Vonthein, C. Claussen, and M. Horger Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. Am. J. Roentgenol., August 1, 2006; 187(2): 404 - 413. [Abstract] [Full Text] [PDF]

				K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis J. Antimicrob. Chemother., February 1, 2004; 53(2): 311 - 317. [Abstract] [Full Text] [PDF]

				S Pepeljnjak, Z Slobodnjak, M Segvic, M Peraica, and M Pavlovic The ability of fungal isolates from human lung aspergilloma to produce mycotoxins Human and Experimental Toxicology, January 1, 2004; 23(1): 15 - 19. [Abstract] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				J. Mosquera, P. A. Warn, J. Morrissey, C. B. Moore, C. Gil-Lamaignere, and D. W. Denning Susceptibility Testing of Aspergillus flavus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1456 - 1462. [Abstract] [Full Text]

				F. Reichenberger, J.M. Habicht, A. Gratwohl, and M. Tamm Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients Eur. Respir. J., January 1, 2001; 19(4): 743 - 755. [Abstract] [Full Text] [PDF]

				M. C. PASTEUR, S. M. HELLIWELL, S. J. HOUGHTON, S. C. WEBB, J. E. FOWERAKER, R. A. COULDEN, C. D. FLOWER, D. BILTON, and M. T. KEOGAN An Investigation into Causative Factors in Patients with Bronchiectasis Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1277 - 1284. [Abstract] [Full Text] [PDF]

				M. J. Allen, R. Harbeck, B. Smith, D. R. Voelker, and R. J. Mason Binding of Rat and Human Surfactant Proteins A and D to Aspergillus fumigatus Conidia Infect. Immun., September 1, 1999; 67(9): 4563 - 4569. [Abstract] [Full Text] [PDF]